Sign In
Last checked at 
27 Feb 2025 07:00
Haleon plc: Preliminary 2024 Full Year Results
27 February 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces its preliminary full year results statement for the year ended 31 December 2024 is available at http://www.rns-pdf.londonstockexchange.com/rns/6119Y_1-2025-2-26.pdf.
The preliminary full year results statement will also be available on the Haleon website www.haleon.com/investors, and the results have been submitted in full unedited text to the Financial Conduct Authority's National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Dividend
Reflecting the strength of free cash flow generation during the year, alongside strong organic profit growth, the Board is proposing a 2024 total dividend of 6.6p per ordinary share which represents a payout ratio of approximately 37% of 2024 adjusted earnings (2023: 35%). This includes a final dividend of 4.6p per ordinary share.
Subject to shareholder approval, the final dividend will be paid on 5 June 2025 to holders of ordinary shares and US American Depositary Shares (ADS) on the register as of 25 April 2025 (the record date). The ex-dividend date for ordinary shares is 24 April 2025 and for US American Depositary Shares (ADS) is 25 April 2025. For ordinary shareholders wishing to participate in the Dividend Reinvestment Programme (DRIP), the election deadline is 15 May 2025. The DRIP is provided by Equiniti Financial Services Limited, more information is available at www.shareview.co.uk/info/drip.
Presentation for analysts and shareholders
A recorded results presentation by Brian McNamara, Chief Executive Officer, and Dawn Allen, Chief Financial Officer, will be available shortly after 7am GMT (8am CET) on 27 February 2025 and can be accessed at www.haleon.com/investors. This will be followed by a Q&A session at 9am GMT (10am CET).
For analysts and shareholders wishing to ask questions on the Q&A call, please use the dial-in details below which will have a Q&A facility:
UK: | +44 (0) 800 358 1035 |
US: | +1 855 979 6654 |
All other: | +44 (0) 203 936 2999 |
Passcode: | 309530 |
An archived webcast of the Q&A call will be available later on the day of the results and can be accessed at www.haleon.com/investors.
This information contains regulated information as per 6.3.7R of the Disclosure and Transparency Rules of the Financial Conduct Authority.
Amanda Mellor
Company Secretary
Enquiries
Investors | Media
| ||
Jo Russell | +44 7787 392441 | Zoë Bird | +44 7736 746167 |
Rakesh Patel | +44 7552 484646 | Victoria Durman | +44 7894 505730 |
Emma White | +44 7823 523562 |
| |
Email: investor-relations@haleon.com |
Email: corporate.media@haleon.com | ||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
Follow the stocks
